HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Protoapigenone, a novel flavonoid, induces apoptosis in human prostate cancer cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase 1/2.

Abstract
In this study, we investigated the anticancer effect of protoapigenone on human prostate cancer cells. Protoapigenone inhibited cell growth through arresting cancer cells at S and G(2)/M phases as well as inducing apoptosis. Blockade of cell cycle by protoapigenone was associated with an increase in the levels of inactivated phospho (p)-Cdc25C (Ser216) and a decrease in the levels of activated p-cyclin B1 (Ser147), cyclin B1, and cyclin-dependent kinase (Cdk) 2. Protoapigenone triggered apoptosis by increasing the levels of cleaved poly(ADP-ribose) polymerase and caspase-3. In addition, activation of p38 mitogen-activated protein kinase (MAPK) and c-Jun NH2-terminal kinase (JNK)1/2 was a critical mediator in protoapigenone-induced cell death. Inhibition of the expression of p38 MAPK and JNK1/2 by pharmacological inhibitors or specific small interfering RNA reversed the protoapigenone-induced apoptosis through decreasing the level of cleaved caspase-3. In contrast, p38 MAPK, but not JNK1/2, was involved in the protoapigenone-mediated S and G(2)/M arrest by modulating the levels of Cdk2 and p-Cdc25C (Ser216). Moreover, in vivo xenograft study showed that protoapigenone had a significant inhibition of prostate tumor growth without major side effects on the mice we tested. This inhibition was associated with induction of apoptosis and activation of p38 MAPK and JNK1/2 in protoapigenone-treated tumor tissues. In conclusion, our results demonstrated protoapigenone suppressed prostate cancer cell growth through the activation of p38 MAPK and JNK1/2, with the potential to be developed as a chemotherapeutic agent for prostate cancer.
AuthorsHsueh-Ling Chang, Yang-Chang Wu, Jinu-Huang Su, Yao-Tsung Yeh, Shyng-Shiou F Yuan
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 325 Issue 3 Pg. 841-9 (Jun 2008) ISSN: 1521-0103 [Electronic] United States
PMID18337475 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Cyclohexanones
  • Flavones
  • protoapigenone
  • Mitogen-Activated Protein Kinase 9
  • Mitogen-Activated Protein Kinase 8
  • p38 Mitogen-Activated Protein Kinases
Topics
  • Animals
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • Apoptosis
  • Cell Cycle (drug effects)
  • Cell Line, Tumor
  • Cyclohexanones (pharmacology, therapeutic use)
  • Flavones (pharmacology, therapeutic use)
  • Humans
  • Male
  • Mice
  • Mice, Nude
  • Mitogen-Activated Protein Kinase 8 (metabolism)
  • Mitogen-Activated Protein Kinase 9 (metabolism)
  • Prostatic Neoplasms (drug therapy, metabolism, pathology)
  • Tumor Burden (drug effects)
  • Xenograft Model Antitumor Assays
  • p38 Mitogen-Activated Protein Kinases (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: